MCID: NRR001
MIFTS: 42

Neuroretinitis

Categories: Neuronal diseases

Aliases & Classifications for Neuroretinitis

MalaCards integrated aliases for Neuroretinitis:

Name: Neuroretinitis 12 15 70
Juxtapapillary Focal Retinitis and Retinochoroiditis 12 70
Retinitis 44 70
Focal Retinitis and Retinochoroiditis, Juxtapapillary 12
Papilloretinitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10176
MeSH 44 D012173
SNOMED-CT 67 410471004
ICD10 32 H30.9
UMLS 70 C0035333 C0154874 C3665438

Summaries for Neuroretinitis

MalaCards based summary : Neuroretinitis, also known as juxtapapillary focal retinitis and retinochoroiditis, is related to retinal vasculitis and cat-scratch disease. An important gene associated with Neuroretinitis is RCVRN (Recoverin), and among its related pathways/superpathways is Visual Cycle in Retinal Rods. The drugs Mannitol and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone marrow.

Wikipedia : 73 Cat-scratch disease (CSD) or felinosis is an infectious disease that most often results from a scratch... more...

Related Diseases for Neuroretinitis

Diseases related to Neuroretinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1285)
# Related Disease Score Top Affiliating Genes
1 retinal vasculitis 30.9 SAG CD4 ACE
2 cat-scratch disease 30.7 CS CRP CD4 ACE
3 night blindness 30.7 TRPM1 SAG CRP
4 syphilis 30.5 CRP CD4 ACE
5 iridocyclitis 30.5 CRP CD4 ACE
6 optic nerve disease 30.4 DPYSL5 CRP CD4
7 iritis 30.4 CRP CD4 ACE
8 papilledema 30.4 CRP CD4 ACE
9 good syndrome 30.3 CRP CD4
10 hypertensive retinopathy 30.3 CRP ACE
11 optic papillitis 30.3 SAG CRP CD4 ACE
12 chickenpox 30.2 CRP CD4
13 ocular tuberculosis 30.1 CD4 ACE
14 bartonellosis 30.1 CS CRP CD4 ACE
15 secondary syphilis 30.1 CRP CD4
16 panuveitis 30.1 SAG CRP CD4 ACE
17 posterior scleritis 30.1 CRP ACE
18 endophthalmitis 30.0 SAG CRP
19 choroiditis 30.0 SAG CD4 ACE
20 chorioretinitis 29.9 SAG CRP CD4 ACE
21 hypopyon 29.9 CRP CD4
22 nocardiosis 29.9 CRP CD4
23 sarcoidosis 1 29.9 CRP CD4 ACE
24 miliary tuberculosis 29.9 CRP CD4
25 chronic meningitis 29.9 CRP CD4
26 urinary tract infection 29.8 CRP ACE
27 bacillary angiomatosis 29.8 CS CD4
28 background diabetic retinopathy 29.8 CRP ACE
29 pneumocystosis 29.8 CRP CD4
30 congenital stationary night blindness 29.7 TRPM1 SAG RCVRN
31 aortic valve insufficiency 29.7 CRP ACE
32 facial paralysis 29.7 CRP CD4 ACE
33 acute retrobulbar neuritis 29.7 SH2D3A CRP
34 cellulitis 29.6 CRP CD4
35 mitral valve insufficiency 29.6 CRP ACE
36 systemic scleroderma 29.6 CRP CD4 ACE
37 pancytopenia 29.6 CRP CD4 ACE
38 cancer-associated retinopathy 29.6 SAG RCVRN ENO1
39 macular dystrophy, dominant cystoid 29.6 RCVRN CAPN5 ACE
40 hantavirus hemorrhagic fever with renal syndrome 29.6 CRP CD4
41 epidemic typhus 29.6 CS CRP CD4
42 melanoma-associated retinopathy 29.5 TRPM1 SAG
43 exanthem 29.5 SH2D3A CRP CD4 ACE
44 acute cystitis 29.4 CRP CD4 ACE
45 severe acute respiratory syndrome 29.4 SH2D3A CRP ACE
46 peripheral nervous system disease 29.3 DPYSL5 CRP CD4 ACE
47 body mass index quantitative trait locus 11 29.1 CS CRP CD4 CAPN5 ACE
48 connective tissue disease 29.1 ENO1 CRP CD4 ACE
49 retinitis pigmentosa 28.2 TRPM1 SAG RCVRN ENO1 CD4 CAPN5
50 neuropathy, ataxia, and retinitis pigmentosa 11.6

Graphical network of the top 20 diseases related to Neuroretinitis:



Diseases related to Neuroretinitis

Symptoms & Phenotypes for Neuroretinitis

Drugs & Therapeutics for Neuroretinitis

Drugs for Neuroretinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 464)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
2
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
3
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 9865442 444025
6
Besifloxacin Approved Phase 4 141388-76-3
7
Cefazolin Approved Phase 4 25953-19-9 33255 656510
8
Dipivefrin Approved Phase 4 52365-63-6 3105
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
10
Povidone-iodine Approved Phase 4 25655-41-8
11
Adapalene Approved Phase 4 106685-40-9 60164
12
Benzoyl peroxide Approved Phase 4 94-36-0 7187
13
Dapsone Approved, Investigational Phase 4 80-08-0 2955
14
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
15
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
16
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
17
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
18
Benserazide Approved, Investigational Phase 4 322-35-0
19
Bromfenac Approved Phase 4 91714-94-2 60726
20
Phenylephrine Approved Phase 4 59-42-7 6041
21
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
22
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
27
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
28
Fluorouracil Approved Phase 4 51-21-8 3385
29
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
30
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
31
Lactitol Approved, Investigational Phase 4 585-86-4 157355
32
Rasagiline Approved Phase 4 136236-51-6 3052776
33
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35 Diuretics, Potassium Sparing Phase 4
36 Sodium Channel Blockers Phase 4
37 Anti-Allergic Agents Phase 4
38 Cephalosporins Phase 4
39 Hypnotics and Sedatives Phase 4
40 Analgesics Phase 4
41 GABA Modulators Phase 4
42 Anesthetics, Intravenous Phase 4
43 Anesthetics, General Phase 4
44 Anti-Anxiety Agents Phase 4
45 Calamus Phase 4
46 Analgesics, Non-Narcotic Phase 4
47 Antirheumatic Agents Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4
49 Vitamins Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 1302)
# Name Status NCT ID Phase Drugs
1 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
2 Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
3 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
4 Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO Unknown status NCT03892434 Phase 4 Intravitreal bevacizumab and dexamethasone implant Injection
5 Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis. Unknown status NCT01669447 Phase 4
6 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Unknown status NCT03405376 Phase 4 Intravitreal aflibercept injection
7 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
8 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
9 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
10 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
11 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
12 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4 lidocaine
13 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
14 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
15 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
16 Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery Unknown status NCT02324166 Phase 4 Cefazolin;Lidocaine
17 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
18 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
19 A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months. Completed NCT01710839 Phase 4 0.5mg Ranibizumab
20 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
21 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
22 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
23 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
24 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
25 Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients Completed NCT00717080 Phase 4
26 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
27 A Clinical Assessment of the Use of RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser and a 5% Benzoyl Peroxide Wash Used in the Morning Compared to the Use of RETIN-A MICRO 0.04% Pump Nightly and a 5% Benzoyl Peroxide Wash in the Morning For the Treatment of Facial Acne Vulgaris Completed NCT00907257 Phase 4 benzoyl peroxide wash;Tretinoin gel
28 An Investigator-Blind, Phase 4 Study Assessing Mitigation of Facial Irritation When Comparing the Use of Two Acne Treatment Products (Retin-A Micro® 0.1 % Pump and Aczone®) With One Treatment Product (Retin-A Micro® 0.1 % Pump) Using a Split-Face Model Completed NCT01313728 Phase 4 Dapsone plus Tretinoin Gel;Tretinoin Gel
29 Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor (VEGF) Treatment in Patients With Branch Retinal Vein Occlusion (BRVO) Completed NCT01027481 Phase 4 Lucentis
30 An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18) Completed NCT01580020 Phase 4 Dexamethasone
31 A Phase IV, Randomised, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD) Completed NCT01972789 Phase 4 Ranibizumab
32 A 12-month, Phase IV, Open-label, Randomized, Active Controlled, 2-arm, Multicenter Study Assessing the Efficacy and Safety of Intravitreal Ranibizumab Combined With Grid&Direct Short Pulse Laser Photocoagulation Versus a PRN Ranibizumab Monotherapy in Japanese Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Completed NCT02953938 Phase 4
33 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4
34 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
35 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
36 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
37 Intravitreal Aflibercept Injection With Panretinal Photocoagulation Versus Early Vitrectomy for Diabetic Vitreous Hemorrhage Completed NCT04153253 Phase 4 Aflibercept Injection [Eylea]
38 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
39 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
40 Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion. Completed NCT02478515 Phase 4 Ranibizumab
41 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
42 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
43 Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis Completed NCT01448018 Phase 4 ranibizumab
44 Dexmedetomidine Versus Ketorolac/ Midazolam on Perioperative Outcome During Retinal Surgery. Completed NCT03143244 Phase 4 Dexmedetomidine group (D);Ketorolac-Midazolam group (KM);Control group (Normal Saline) (C)
45 Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
46 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Completed NCT02274259 Phase 4 Aflibercept;Ranibizumab
47 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Aflibercept (Eylea, BAY86-5321)
48 A 6-Month, Single Site, Masked, Randomized,Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4 Avastin;Osurdex;Avastin
49 Comparison of Dexmedetomidine vs. Propofol in Vitreoretinal Surgery Under Sub-Tenon's Block Completed NCT01001429 Phase 4 Dexmedetomidine infusion;propofol
50 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4 dexamethasone intravitreal implant

Search NIH Clinical Center for Neuroretinitis

Cochrane evidence based reviews: retinitis

Genetic Tests for Neuroretinitis

Anatomical Context for Neuroretinitis

MalaCards organs/tissues related to Neuroretinitis:

40
Eye, Retina, Bone Marrow, Endothelial, Bone, Brain, Kidney

Publications for Neuroretinitis

Articles related to Neuroretinitis:

(show top 50) (show all 13104)
# Title Authors PMID Year
1
Luteolin delays photoreceptor degeneration in a mouse model of retinitis pigmentosa. 61
33642401 2021
2
Topical delivery of nerve growth factor for treatment of ocular and brain disorders. 61
33510063 2021
3
Short-term oral albendazole therapy for diffuse unilateral subacute neuroretinitis: A case report. 61
33748536 2021
4
Rickettsial neuroretinitis: A report of 2 cases. 61
33732952 2021
5
Cytomegalovirus retinitis following dexamethasone intravitreal implant. 61
33732951 2021
6
Multisensory perception in Argus II retinal prosthesis patients: Leveraging auditory-visual mappings to enhance prosthesis outcomes. 61
33607599 2021
7
A CRISPR and high-content imaging assay compliant with ACMG/AMP guidelines for clinical variant interpretation in ciliopathies. 61
33095315 2021
8
Absence of SCAPER causes male infertility in humans and Drosophila by modulating microtubule dynamics during meiosis. 61
32527956 2021
9
Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases. 61
33641047 2021
10
Bi-allelic missense variant, p.Ser35Leu in EXOSC1 is associated with pontocerebellar hypoplasia. 61
33463720 2021
11
Post COVID-19 opportunistic candida retinitis: A case report. 61
33727474 2021
12
Proteomic analysis of aqueous humor from cataract patients with retinitis pigmentosa. 61
32869287 2021
13
Intravitreal quantum dots for retinitis pigmentosa: a first-in-human safety study. 61
33739144 2021
14
Clinical trial design for neuroprotection in RHO autosomal dominant retinitis pigmentosa; outcome measure considerations. 61
33406961 2021
15
Multimodal imaging of retinitis pigmentosa associated with Mainzer-Saldino syndrome. 61
33393400 2021
16
MICROSTRUCTURAL CHANGES IN CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA AFTER INTRAVITREAL DEXAMETHASONE IMPLANT INJECTION. 61
32796442 2021
17
Infectious Uveitis after Local Steroid and/or Methotrexate Injections at A Tertiary Referral Center in New Zealand: A Case Series. 61
33792480 2021
18
Clinical profile and visual outcome of intraocular inflammation associated with cat-scratch disease in Japanese patients. 61
33797675 2021
19
Clinical spectrum, genetic associations and management outcomes of Coats-like exudative retinal vasculopathy in autosomal recessive retinitis pigmentosa. 61
33441055 2021
20
An Unusual Presentation of Hemorrhagic Disease in an Infant: A Probable Case of Abetalipoproteinemia. 61
32433446 2021
21
Correction to: Development of cytomegalovirus retinitis after negative conversion of cytomegalovirus antigenemia due to systemic antiviral therapy. 61
33313971 2021
22
Development of cytomegalovirus retinitis after negative conversion of cytomegalovirus antigenemia due to systemic antiviral therapy. 61
33185730 2021
23
Varicella Zoster Viral Retinitis following Chimeric Antigenic Response T-cell Therapy for B-cell Lymphoma. 61
33797314 2021
24
Epilepsy in MT-ATP6 - related mils/NARP: correlation of elettroclinical features with heteroplasmy. 61
33476484 2021
25
The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement. 61
33743793 2021
26
A smartphone based method for mouse fundus imaging. 61
33675778 2021
27
Structural aspects of rod opsin and their implication in genetic diseases. 61
33728518 2021
28
Defining Phenotype, Tropism, and Retinal Gene Therapy Using Adeno-Associated Viral Vectors (AAVs) in New-Born Brown Norway Rats with a Spontaneous Mutation in Crb1. 61
33808129 2021
29
Gene therapy for inherited retinal diseases: progress and possibilities. 61
33689657 2021
30
Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials. 61
33799995 2021
31
Model-based comparison of current flow in rod bipolar cells of healthy and early-stage degenerated retina. 61
33794197 2021
32
Low Immunogenicity and Immunosuppressive Properties of Human ESC- and iPSC-Derived Retinas. 61
33770500 2021
33
Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system. 61
33434618 2021
34
Terminal Peptide Extensions Augment the Retinal IMPDH1 Catalytic Activity and Attenuate the ATP-induced Fibrillation Events. 61
33733369 2021
35
Glow in the dark: Using a heat-sensitive camera for blind individuals with prosthetic vision. 61
33780753 2021
36
Comparison of developmental dynamics in human fetal retina and human pluripotent stem cell derived retinal tissue. 61
33677999 2021
37
Photoreceptor precursor cell integration into rodent retina after treatment with novel glycopeptide PKX-001. 61
33779072 2021
38
OCT-angiography assessing quiescent and active choroidal neovascularization in retinitis pigmentosa associated with PRPH2 pathogenic variant. 61
33736480 2021
39
Impairments of Photoreceptor Outer Segments Renewal and Phototransduction Due to a Peripherin Rare Haplotype Variant: Insights from Molecular Modeling. 61
33801777 2021
40
The Major Ciliary Isoforms of RPGR Build Different Interaction Complexes with INPP5E and RPGRIP1L. 61
33808286 2021
41
Cytomegalovirus optic neuropathy in a young immunocompetent patient. 61
33721197 2021
42
Posterior Subhyaloid Precipitates: 'KPs' of the Posterior Segment. 61
33734863 2021
43
Clinical applications of microperimetry in RPGR-related retinitis pigmentosa: a review. 61
33783139 2021
44
Ellipsoid zone optical intensity reduction as an early biomarker for retinitis pigmentosa. 61
32701217 2021
45
Fructus Lycii and Salvia miltiorrhiza Bunge extract alleviate retinitis pigmentosa through Nrf2/HO-1 signaling pathway. 61
33684515 2021
46
Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3. 61
33807610 2021
47
Clinical Characteristics, Differential Diagnosis and Genetic Analysis of Concentric Retinitis Pigmentosa. 61
33809962 2021
48
Correction to: The impact of macular edema on microvascular and metabolic alterations in retinitis pigmentosa. 61
33064197 2021
49
The impact of macular edema on microvascular and metabolic alterations in retinitis pigmentosa. 61
32910309 2021
50
AAV-CRB2 protects against vision loss in an inducible CRB1 retinitis pigmentosa mouse model. 61
33575434 2021

Variations for Neuroretinitis

Expression for Neuroretinitis

Search GEO for disease gene expression data for Neuroretinitis.

Pathways for Neuroretinitis

Pathways related to Neuroretinitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.77 SAG RCVRN CRP

GO Terms for Neuroretinitis

Biological processes related to Neuroretinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of calcium ion transport GO:0051924 8.62 RCVRN CD4

Sources for Neuroretinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....